Germany-based Affimed NV has priced its previously announced US offering of 12 million shares at $2.50 per common share. After deducting underwriting discounts, the net proceeds are expected to be about $28.2 million. The offering is expected to close on or about 13 November.
Based in Heidelberg, Affimed is a clinical-stage company with three ongoing trials in lymphoma. On 7 November, it announced US Food and Drug Administration approval for the start of a fourth trial in patients with advanced cancers expressing the epidermal growth factor receptor (EGFR).